CONTEXT: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis may underlie the metabolic syndrome, but whether circulating cortisol levels predict cardiovascular end points is less clear. People with type 2 diabetes are at increased cardiovascular disease risk and thus are suitable to study associations of plasma cortisol with cardiovascular risk. OBJECTIVE: We aimed to assess whether altered HPA axis activity was associated with features of the metabolic syndrome and ischemic heart disease in people with type 2 diabetes. DESIGN AND SETTING: We conducted a cross-sectional cohort study in the general community, including 919 men and women aged 67.9 (4.2) yr with type 2 diabetes (the Edinburgh Type 2 Diabetes Study). INTERVENTION: We measured fasting morning plasma cortisol. MAIN OUTCOME MEASUREMENT: Associations between cortisol levels, features of the metabolic syndrome, obesity, and ischemic heart disease were determined. RESULTS: Elevated plasma cortisol levels were associated with raised fasting glucose and total cholesterol levels (P < 0.001). These findings remained significant after adjustment for potential confounding factors (P < 0.001). Elevated cortisol levels were associated with prevalent ischemic heart disease (>800 vs. <600 nmol/liter; odds ratio, 1.58; P = 0.02). This association remained significant after adjustment for duration and control of diabetes and other cardiovascular risk factors (P = 0.03). CONCLUSIONS: The previously described associations between HPA axis activation and features of the metabolic syndrome are present among people with type 2 diabetes. Elevated plasma cortisol is also associated with a greater prevalence of ischemic heart disease, independent of conventional risk factors. Understanding the role of cortisol in the pathogenesis of ischemic heart disease merits further exploration.
CONTEXT: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis may underlie the metabolic syndrome, but whether circulating cortisol levels predict cardiovascular end points is less clear. People with type 2 diabetes are at increased cardiovascular disease risk and thus are suitable to study associations of plasma cortisol with cardiovascular risk. OBJECTIVE: We aimed to assess whether altered HPA axis activity was associated with features of the metabolic syndrome and ischemic heart disease in people with type 2 diabetes. DESIGN AND SETTING: We conducted a cross-sectional cohort study in the general community, including 919 men and women aged 67.9 (4.2) yr with type 2 diabetes (the Edinburgh Type 2 Diabetes Study). INTERVENTION: We measured fasting morning plasma cortisol. MAIN OUTCOME MEASUREMENT: Associations between cortisol levels, features of the metabolic syndrome, obesity, and ischemic heart disease were determined. RESULTS: Elevated plasma cortisol levels were associated with raised fasting glucose and total cholesterol levels (P < 0.001). These findings remained significant after adjustment for potential confounding factors (P < 0.001). Elevated cortisol levels were associated with prevalent ischemic heart disease (>800 vs. <600 nmol/liter; odds ratio, 1.58; P = 0.02). This association remained significant after adjustment for duration and control of diabetes and other cardiovascular risk factors (P = 0.03). CONCLUSIONS: The previously described associations between HPA axis activation and features of the metabolic syndrome are present among people with type 2 diabetes. Elevated plasma cortisol is also associated with a greater prevalence of ischemic heart disease, independent of conventional risk factors. Understanding the role of cortisol in the pathogenesis of ischemic heart disease merits further exploration.
Authors: Deborah J Wake; Roland H Stimson; Garry D Tan; Natalie Z M Homer; Ruth Andrew; Fredrik Karpe; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2007-02-27 Impact factor: 5.958
Authors: Z S Lee; J C Chan; V T Yeung; C C Chow; M S Lau; G T Ko; J K Li; C S Cockram; J A Critchley Journal: Diabetes Care Date: 1999-09 Impact factor: 19.112
Authors: Hannah Bruehl; Melanie Rueger; Isabel Dziobek; Victoria Sweat; Aziz Tirsi; Elizabeth Javier; Alyssa Arentoft; Oliver T Wolf; Antonio Convit Journal: J Clin Endocrinol Metab Date: 2007-04-10 Impact factor: 5.958
Authors: E J Brunner; H Hemingway; B R Walker; M Page; P Clarke; M Juneja; M J Shipley; M Kumari; R Andrew; J R Seckl; A Papadopoulos; S Checkley; A Rumley; G D O Lowe; S A Stansfeld; M G Marmot Journal: Circulation Date: 2002-11-19 Impact factor: 29.690
Authors: Jackie F Price; Rebecca M Reynolds; Rory J Mitchell; Rachel M Williamson; F Gerald R Fowkes; Ian J Deary; Amanda J Lee; Brian M Frier; Peter C Hayes; Mark W J Strachan Journal: BMC Endocr Disord Date: 2008-12-11 Impact factor: 2.763
Authors: Melanie Schorr; Elizabeth A Lawson; Laura E Dichtel; Anne Klibanski; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Beverly H Brummett; Cynthia M Kuhn; Stephen H Boyle; Michael A Babyak; Ilene C Siegler; Redford B Williams Journal: Biol Psychol Date: 2011-10-01 Impact factor: 3.251
Authors: H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153
Authors: Amy E B Packard; Sriparna Ghosal; James P Herman; Stephen C Woods; Yvonne M Ulrich-Lai Journal: Psychoneuroendocrinology Date: 2014-05-29 Impact factor: 4.905
Authors: G Noppe; E L T van den Akker; Y B de Rijke; J W Koper; V W Jaddoe; E F C van Rossum Journal: Int J Obes (Lond) Date: 2016-06-24 Impact factor: 5.095